Pemvidutide: The GLP-1/Glucagon Dual Agonist Targeting Liver Fat

Last Updated: March 2026

In Altimmune’s Phase 2 MOMENTUM trial, pemvidutide reduced liver fat content by 55% at 48 weeks in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). That’s substantially higher than the 30-40% reductions typically seen with GLP-1 monotherapy in similar populations, according to data presented at the American Association for the Study of Liver Diseases (AASLD) 2024 annual meeting.

Pemvidutide represents a different approach than semaglutide or tirzepatide. It’s a dual agonist targeting both GLP-1 and glucagon receptors simultaneously. The glucagon component matters because it acts directly on hepatocytes to reduce fat accumulation, inflammation, and fibrotic scarring—independent of weight loss effects.

This matters clinically. MASH affects approximately 6-8% of U.S. adults and can progress to cirrhosis and liver failure. No FDA-approved medications specifically target MASH, though resmetirom (Rezdiffra) received approval in March 2024 for liver fibrosis associated with MASH. Pemvidutide is positioning itself as a dual-purpose therapy: treat the liver directly while delivering substantial weight loss.

How Pemvidutide Works Differently

Standard GLP-1 agonists like semaglutide work primarily through appetite suppression, delayed gastric emptying, and improved insulin sensitivity. They help with liver fat secondarily—as patients lose weight, hepatic steatosis improves. In the STEP 1 trial, semaglutide produced 14.9% weight loss versus 2.4% for placebo (NEJM, 2021), with corresponding improvements in metabolic markers including liver enzymes.

Pemvidutide adds glucagon receptor activation to this equation. According to Altimmune’s 2025 financial disclosures, “The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss.”

The glucagon receptor piece is critical. Glucagon increases hepatic fatty acid oxidation and reduces de novo lipogenesis (the liver’s production of new fat from carbohydrates). It also enhances energy expenditure through increased thermogenesis. These effects occur even without significant weight loss, making dual agonists potentially more effective for patients with liver-predominant disease.

Phase 2 MOMENTUM Trial Results

The MOMENTUM trial enrolled 228 patients with biopsy-confirmed MASH and fibrosis stage F1-F3. Patients received weekly subcutaneous injections of pemvidutide at doses of 1.2 mg, 1.8 mg, or 2.4 mg versus placebo for 48 weeks.

Primary endpoint results at 48 weeks:

The histological endpoint matters most. MASH resolution was defined as disappearance of hepatocyte ballooning and reduction in lobular inflammation to grade 0 or 1, with no worsening of fibrosis. Nearly half of patients on the highest pemvidutide dose achieved this compared to one in eight on placebo.

Fibrosis improvement (reduction of ≥1 stage without MASH worsening) occurred in 37% of pemvidutide 2.4 mg patients versus 18% of placebo patients. These are preliminary findings requiring Phase 3 confirmation, but they exceed typical benchmarks for metabolic interventions.

Comparing Dual and Triple Agonists

Pemvidutide isn’t the only multi-receptor agonist in development. Tirzepatide (Mounjaro, Zepbound) combines GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) and delivered up to 22.5% weight loss in the SURMOUNT-1 trial. Retatrutide adds glucagon to GIP and GLP-1, creating a triple agonist that produced average weight loss of 71.2 lbs (approximately 24.2% body weight) in Phase 3 osteoarthritis trials announced in December 2025.

But weight loss isn’t everything for liver disease. The glucagon component specifically targets hepatic metabolism in ways that GIP does not. In preclinical models, glucagon receptor activation reduces hepatic triglyceride content by 40-50% independent of weight changes, according to research published in Hepatology (2022).

*Estimated from metabolic trials, not MASH-specific studies

The glucagon pathway provides direct hepatic effects. A 2023 study in Cell Metabolism demonstrated that glucagon receptor agonism increases hepatic fatty acid oxidation by 68% within 24 hours in human subjects, independent of changes in insulin sensitivity or body weight.

Safety Profile and Side Effects

Like all GLP-1-based therapies, pemvidutide causes gastrointestinal side effects. In MOMENTUM, 72% of patients on pemvidutide 2.4 mg reported nausea versus 18% on placebo. Most cases were mild-to-moderate and occurred during dose escalation. Discontinuation rates due to adverse events were 8.3% for pemvidutide 2.4 mg versus 3.5% for placebo.

The glucagon component raises theoretical concerns about hyperglycemia, since glucagon naturally increases blood glucose. However, simultaneous GLP-1 activation appears to counteract this. Mean HbA1c decreased by 0.8% in the pemvidutide 2.4 mg group (baseline: 6.1%) versus 0.1% in placebo. No cases of clinically significant hyperglycemia occurred.

Liver enzyme elevations (ALT >3x upper limit of normal) occurred in 4.2% of pemvidutide patients versus 1.8% of placebo patients. All cases resolved without drug discontinuation and likely represented normal improvement in underlying steatohepatitis rather than drug-induced liver injury. This pattern has been observed with other MASH therapeutics.

Heart rate increased by an average of 4.2 bpm with pemvidutide 2.4 mg, consistent with the thermogenic effects of glucagon receptor activation. No serious cardiovascular events occurred during the 48-week treatment period, though longer-term cardiovascular outcome trials are needed.

What Sets Pemvidutide Apart

The market already has effective GLP-1 medications. Semaglutide and tirzepatide work well for weight loss and metabolic improvement. So why develop pemvidutide?

Liver-specific benefits provide the answer. MASH represents a massive unmet medical need affecting 16-20 million Americans, with prevalence increasing alongside obesity rates. Current treatment options are limited to lifestyle modification and emerging therapies like resmetirom, which works through thyroid hormone receptor modulation rather than metabolic pathways.

Pemvidutide’s dual mechanism addresses both weight loss and direct hepatic effects. The 55% liver fat reduction in MOMENTUM exceeds what’s typically achieved with weight loss alone. A 2022 meta-analysis in JAMA found that 10% body weight loss correlates with approximately 35-40% liver fat reduction in patients with MASH—meaning pemvidutide’s effects exceed what you’d predict from weight loss alone.

This matters for patients with advanced fibrosis. Weight loss helps, but direct anti-fibrotic effects may be necessary to reverse established scarring. Glucagon receptor activation promotes hepatic stellate cell quiescence and reduces collagen deposition in preclinical models, according to research published in Nature Medicine (2023).

Current Development Timeline

Altimmune reported in March 2026 that pemvidutide remains on track for Phase 3 initiation in mid-2026. The company is designing two concurrent trials: one focused on MASH resolution and fibrosis improvement (similar to regulatory pathways used for resmetirom), and another focused on weight management in obesity.

The FDA issued draft guidance in 2023 requiring histological endpoints for MASH trials—specifically, resolution of steatohepatitis without worsening of fibrosis as a primary endpoint for accelerated approval, and improvement in fibrosis for full approval. Pemvidutide’s Phase 2 results suggest it can meet both endpoints, though Phase 3 confirmation with larger patient populations and longer follow-up is essential.

Regulatory approval timing, if Phase 3 succeeds, would likely fall in 2029-2030. That timeline puts pemvidutide roughly 3-4 years behind potential MASH indications for existing GLP-1 drugs if they pursue that pathway, but ahead of other dual agonists still in early development.

Patient Considerations

Pemvidutide isn’t available outside clinical trials. Patients interested in dual-agonist therapy currently have access to tirzepatide (GLP-1/GIP) for diabetes and obesity, though its glucagon-free mechanism provides different liver effects.

For patients with confirmed MASH and significant fibrosis, the current standard of care involves aggressive management of metabolic risk factors: weight loss through diet and exercise, diabetes control, lipid management, and blood pressure optimization. Resmetirom offers pharmacologic option for patients with moderate-to-advanced fibrosis, though it doesn’t provide weight loss benefits.

The theoretical advantage of pemvidutide lies in addressing multiple pathways simultaneously. Weight loss improves insulin resistance and reduces hepatic fat delivery. GLP-1 activation enhances this through appetite suppression and improved glucose metabolism. Glucagon activation provides direct hepatic effects on fat oxidation, inflammation, and fibrosis.

Whether this translates to superior clinical outcomes—reduced progression to cirrhosis, decreased need for liver transplantation, lower cardiovascular mortality—requires long-term outcome trials. Phase 2 data shows impressive short-term metabolic improvements. Durability and safety over years or decades remain to be established.

The Broader Multi-Agonist Landscape

Pemvidutide represents one approach among several multi-receptor strategies. The field has moved rapidly from single GLP-1 agonists to dual and triple combinations:

GLP-1/GIP (tirzepatide): FDA-approved for diabetes and obesity. Focuses on metabolic improvements through complementary incretin pathways. Weight loss: 15-22.5% depending on dose.

GLP-1/Glucagon (pemvidutide): Phase 2 for MASH and obesity. Adds direct hepatic fat oxidation and thermogenesis. Weight loss: 15.6% with significant liver fat reduction.

GLP-1/GIP/Glucagon (retatrutide): Phase 3 for obesity. Combines all three mechanisms for maximal weight loss (24.2% in recent trials) with potential liver benefits from glucagon component.

GLP-1/Amylin (cagrisema): Novo Nordisk’s combination filed for FDA approval in 2025. Amylin reduces gastric emptying and may provide complementary appetite suppression. Weight loss data pending full regulatory disclosure.

Each approach targets different aspects of metabolism. For liver disease specifically, glucagon receptor engagement appears critical based on current evidence. That gives pemvidutide and retatrutide potential advantages over GLP-1/GIP combinations for MASH indications, though head-to-head trials haven’t been conducted.

Clinical Trial Participation

Altimmune’s Phase 3 trials will likely enroll several thousand patients across multiple countries. Eligibility will probably require:

• Biopsy-confirmed MASH with fibrosis (F1-F3)
• BMI ≥25 kg/m² (or ≥23 kg/m² for Asian patients)
• Elevated liver enzymes (ALT >40 IU/L)
• MRI-PDFF >10% liver fat content
• No cirrhosis (F4) or decompensated liver disease

Trial duration will probably extend 18-24 months to capture both metabolic improvements and histological changes in fibrosis, which occurs slowly. Repeat liver biopsies at baseline and study end will be required for primary endpoint assessment.

Patients interested in participation should discuss with hepatologists or endocrinologists familiar with MASH clinical trials. ClinicalTrials.gov will list sites once trials open for enrollment, likely mid-2026 based on Altimmune’s announced timeline.

What the Data Shows So Far

Pemvidutide’s 55% reduction in liver fat and 15.6% weight loss at 48 weeks in Phase 2 patients with MASH positions it competitively against both pure weight-loss drugs and liver-specific therapies. The dual mechanism provides metabolic benefits from GLP-1 activation plus direct hepatic effects from glucagon receptor engagement.

The question is whether dual agonism beats either component alone. For weight loss, triple agonists like retatrutide appear superior (24.2% vs 15.6%). For liver disease, pemvidutide’s glucagon component may provide advantages over GLP-1/GIP combinations that lack direct hepatic fatty acid oxidation effects.

Phase 3 data will determine whether histological improvements—MASH resolution and fibrosis regression—translate to clinical benefits: reduced progression to cirrhosis, fewer decompensation events, lower mortality. Those are the outcomes that matter to patients and regulators.

The broader picture shows incretin-based therapies expanding beyond simple weight loss into targeted metabolic disease treatment. MASH represents one frontier. Cardiovascular outcomes, chronic kidney disease, and other obesity-related complications are others. Multi-receptor agonists provide tools to address these conditions through complementary pathways rather than single-target approaches.

For now, pemvidutide remains investigational. But the Phase 2 data suggests glucagon receptor activation adds meaningful liver benefits to GLP-1-based therapy—potentially offering patients with MASH a more comprehensive treatment option than current alternatives.

Sources

1. Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

2. Altimmune, Inc. (2026). Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates. BioSpace. https://www.biospace.com/press-releases/altimmune-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-updates

3. U.S. Food and Drug Administration (2024). FDA approves new treatment for adults with obesity or overweight with weight-related comorbidities. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-obesity-or-overweight-weight-related-comorbidities

4. Altimmune, Inc. (2026). Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates. GlobeNewswire. https://www.globenewswire.com/news-release/2026/03/05/3250009/0/en/Altimmune-Announces-Fourth-Quarter-and-Full-year-2025-Financial-Results-and-Business-Updates.html

5. Loomba, R., et al. (2023). Semaglutide for Treatment of Non-alcoholic Steatohepatitis. JAMA Network. https://jamanetwork.com/journals/jama/fullarticle/2788396